SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals soars on getting EIR with VAI status for USA manufacturing facility

27 Nov 2025 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 1941.90, up by 20.95 points or 1.09% from its previous closing of Rs. 1920.95 on the BSE.

The scrip opened at Rs. 1934.95 and has touched a high and low of Rs. 1958.00 and Rs. 1925.00 respectively. So far 32058 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.

Last one week high and low of the scrip stood at Rs. 1958.00 and Rs. 1825.00 respectively. The current market cap of the company is Rs. 54645.36 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.38% and 13.97% respectively.

Glenmark Pharmaceuticals has received Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the United States Food & Drug Administration (USFDA) for its formulations manufacturing facility situated in Monroe, North Carolina, USA. This is following an inspection conducted by the Agency from June 09 to June 17 2025. The commercial manufacturing at the Monroe site will now restart.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×